Chandra Shruti, Sheth Jay, Anantharaman Giridhar, Gopalakrishnan Mahesh
Department of Vitreo-Retina, Giridhar Eye Institute, Ponneth Temple Road, Kadavanthara, Kochi, India.
Am J Ophthalmol Case Rep. 2018 Jan 4;9:41-44. doi: 10.1016/j.ajoc.2018.01.006. eCollection 2018 Mar.
To report regression of neovascularization and reperfusion of ischemic areas of the retina on Wide-field Digital Fluorescein Angiography following anti-vascular endothelial growth factor injections in a patient with active Proliferative Diabetic Retinopathy.
Case report of sixty-one-year-old male patient with proliferative diabetic retinopathy and diabetic macular edema documented on wide field digital fluorescein angiography. The patient was treated with three intravitreal injections of ranibizumab given at monthly intervals. Repeat angiography after third intravitreal injection revealed complete regression of new vessels. Moreover, there was evident improvement in perfusion in the previously noted ischemic areas of the retina.
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are a valuable treatment option for reversing neovascularization in eyes with proliferative diabetic retinopathy with fewer side effects when compared to standard pan-retinal photocoagulation. Additionally, we also illustrate restoration of retinal perfusion post anti-VEGF therapy indicative of pre-existingsalvageableischemic retina tissue.
报告在一名患有活动性增殖性糖尿病视网膜病变的患者中，抗血管内皮生长因子注射后，广角数字荧光素血管造影显示视网膜缺血区域的新生血管消退和再灌注情况。
一名61岁男性患者的病例报告，该患者患有增殖性糖尿病视网膜病变和糖尿病性黄斑水肿，广角数字荧光素血管造影记录了相关情况。患者接受了每月一次的三次玻璃体内注射雷珠单抗治疗。第三次玻璃体内注射后重复血管造影显示新生血管完全消退。此外，视网膜先前记录的缺血区域的灌注有明显改善。
与标准的全视网膜光凝相比，玻璃体内注射抗血管内皮生长因子（抗VEGF）是一种有价值的治疗选择，可用于逆转增殖性糖尿病视网膜病变患者的新生血管，且副作用较少。此外，我们还说明了抗VEGF治疗后视网膜灌注的恢复，这表明存在可挽救的缺血性视网膜组织。
